Letter from the CEO, CannMedTM 2024 Highlights, and More

Letter from the CEO

This summer has been challenging for the biotech industry, and Canurta Therapeutics has felt the impact. As we navigate through these tough times, the question on everyone’s mind is: When will biotech financing return?

The rising interest rates have significantly limited funding, but recent developments suggest that relief may be on the way, with rate cuts expected in both the U.S. and Canada.

Despite these external challenges, we at Canurta are committed to controlling our own destiny and actively working to shape our future. Over the past few months, we’ve engaged in numerous initiatives aimed at driving our company forward:

In late August, we participated in the Biotechgate Digital Partnering event, where we met with pharma business development consultants to explore new revenue opportunities and potential collaborations.

Shortly after, we joined the Ontario government delegation at RESI Boston, an event dedicated to showcasing the incredible work being done in Canada’s biotech sector.

Additionally, we were invited to the AbbVie Partnering Day in partnership with OBIO, where we had the opportunity to discuss our assets that focus on combating neurodegeneration and inflammation.

On the research front, our poster on the Therapeutic Potential of Cannabis-Derived Formulations in Mitigating Motor Neuron Disease was accepted for presentation at the 35th MNDA International Symposium in Montreal this December. This platform will allow us to showcase new data, including our Gene Sequencing results, which demonstrate the superior therapeutic potential of our formulation CNR-401 over Edaravone, the current market standard.

Our commitment to the ALS community remains strong. We recently hosted IAMALS’ clinical trial team, gaining valuable insights that will guide our future drug development efforts. In July, IAMALS brought their clinical trial team to meet with us, where they listened to a presentation from myself and Pamela Kisun, our Head of Operations and Clinical Ops Lead, and shared perspectives that will help shape our direction moving forward.

We’re also excited about an upcoming collaboration with a leading U.S. institute on our first-in-human studies.

While we’re making progress, we need your support to continue this journey.

Catalyzing Growth with Early-Stage Investments

Canurta Therapeutics is pleased to announce the launch of our Pre-Seed funding round, with a target of raising CAD $5 million. With 20% already committed, these funds will be pivotal in advancing our pipeline through critical stages, including the upcoming Investigator-Initiated Trial (IIT) and progress toward Registration Trials.

We are engaging with angel funds, private investors, and accredited individuals who share our vision and are interested in early-stage opportunities. Our partners in this round will have a unique opportunity to support and benefit from the development of innovative therapeutic solutions.

Key Highlights:

• Funding Goal: CAD $5 million (20% committed)

• Pre-Seed Valuation: CAD $20 million

• Equity Offered: 20%

• Use of Funds: Primarily focused on Research & Development (52%), with additional allocations for Salaries and Staffing (20%), Manufacturing and Production (10%), and other essential operational needs.

Additionally, Canurta has secured a $5 million convertible debt to expedite readiness for Seed financing, accompanied by a PIPE Term Sheet commitment contingent upon public listing and execution within 36 months.

This marks an important milestone for Canurta as we work towards becoming a leader in the biotechnology sector. We invite those who are passionate about innovation and growth to join us in this journey.

For more information and to explore investment opportunities, please contact us at investors@canurta.com.

Thank you for standing with us.

Sincerely,

Akeem Gardner

CEO, Canurta Therapeutics

Highlights from CannMedTM 24 Innovation & Investment Summit

Earlier this year at the CannMed 24 Innovation & Investment Summit, our CEO, Akeem Gardner, presented on "The Effect of Cannflavins on Mitigating Motor Neuron Disease." His presentation explored the potential of cannflavins in addressing neurodegenerative diseases like ALS.

This talk highlighted our progress in neurological health, showcasing Canurta’s innovative approach to botanical therapeutics for critical medical needs.

Click below to watch the full presentation and learn more about our research and its implications for ALS treatment.

View Presentation

Canurta's August Milestones

Research and Development

The research and development team has successfully synthesized a new methylated flavonoid compound using our proprietary biosynthesis platform. This innovative compound is scheduled to undergo testing for its anticancer activity starting in September.